Clinical Research Directory

Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Patient, ≥ 60 years-old - \< 75 years-old, with established diagnosis of de novo or secondary AML with intermediate-risk or adverse-risk cytogenetic profile, or with established myelodysplasic syndromes (RAEB), in pathologically confirmed complete remission following anti-leukemic induction therapy (\<5% blasts) * Contra-indication to conditioning regimen in conventional allogeneic transplantation Exclusion Criteria: * Patient with established diagnosis of acute myeloid leukemia with standard-risk cytogenetic profile * Promyelocytic leukemia t(15;17) * CBF-AML t(8;21) or inv(16) * Normal karyotype with a favorable molecular profile: NPM1+ and FLT3-; NPM1+, FLT3- and double mutation CEBPα or chronic myeloid leukemia in blastic phase * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation